TransMedics Group, Inc. TMDX recently issued a statement refuting the claims made in a report by short-seller Scorpion ...

Group addressed what we believe are inaccurate and misleading claims made in a short-seller report issued by Scorpion ...

Shares of organ transplant innovator TransMedics Group (NASDAQ: TMDX) fell 15.7% through Thursday trading, according to data ...

TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

If you purchased TransMedics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a ...

Scorpion Capital accuses TransMedics of fraudulent practices, kickbacks, and racketeering, setting a price target of $0.00. TransMedics denies the claims, stating the allegations aim to manipulate ...

NDAQ:TMDX) The Schall Law Firm Invites Investors With Losses To Join An Inquiry Into TransMedics Group, Inc. For Securities Fraud ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ:TMDX). Such ...

We maintain cautious stance on TransMedics investment due to high-risk factors. Read here for an analysis of TMDX stock drop and future prospects.

Jan. 13, 2025 /PRNewswire/ -- TransMedics Group ... and misleading claims made in a short-seller report issued by Scorpion Capital on January 10, 2025. In response, the company issued the ...

TransMedics has previously touted its OCS as "the only FDA approved, portable, multi-organ, warm perfusion technology platform" and its NOP as providing a more efficient organ procurement process.

ANDOVER, Mass., Jan. 13, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with ...